Comparative real-world Progression Free Survival of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer Patients with Bone Metastases - PubMed
5 hours ago
- #CDK4/6 inhibitors
- #breast cancer
- #bone metastases
- This study compared real-world progression-free survival (rwPFS) and overall survival (OS) of three CDK4/6 inhibitors (abemaciclib, ribociclib, palbociclib) combined with endocrine therapy in HR+/HER2- metastatic breast cancer patients with bone metastases.
- Palbociclib showed shorter rwPFS (22 months) and OS (47 months) compared to both abemaciclib (32 and 60 months) and ribociclib (35 and 64 months), with no significant difference observed between abemaciclib and ribociclib.
- The results, consistent after propensity score matching and inverse probability of treatment weighting adjustments, suggest ribociclib and abemaciclib may offer superior outcomes compared to palbociclib for this patient population in a real-world setting.